wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q28083239-81182E44-B839-4B47-B234-2EB7EEC31287
Q28083239-81182E44-B839-4B47-B234-2EB7EEC31287
BestRank
Statement
http://www.wikidata.org/entity/statement/Q28083239-81182E44-B839-4B47-B234-2EB7EEC31287
Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance
P2860
Q28083239-81182E44-B839-4B47-B234-2EB7EEC31287
BestRank
Statement
http://www.wikidata.org/entity/statement/Q28083239-81182E44-B839-4B47-B234-2EB7EEC31287
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
8ab38df888c436e5518edc020d451f3c0ceb7ba4
P2860
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.